智飞生物：上半年净亏损5.97亿元 同比转亏

Core Viewpoint - The company reported a significant decline in revenue and a net loss for the first half of 2025, indicating financial challenges and a shift from profitability to loss compared to the previous year [1] Financial Performance - The company's operating revenue for the reporting period was 4.919 billion yuan, representing a year-on-year decrease of 73.06% [1] - The net profit attributable to shareholders was a loss of 0.597 billion yuan, contrasting with a profit of 2.234 billion yuan in the same period last year, marking a significant year-on-year decline [1] Dividend Policy - The company announced plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [1]